Sensible Biotechnologies Secures $47 Million to Advance Naturally Modified mRNA Platform and Unlock Next Generation of mRNA MedicinesSensible Biotechnologies (“Sensible”), a biotechnology company developing a first-of-its-kind platform for naturally modified mRNA medicines, today announced that it has secured $47 million in financing to advance and scale its integrated mRNA technology. The financing includes a Series A and up to $20 million in non-dilutive funding from the Government of Slovakia and the European Union.
